Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 1222

Next Previous
X
Search
Drug Profile

AZD 1222

Alternative Names: AZD-1222; ChAdOx1 nCoV-19; ChAdOx1 nCoV-19-vaccine; ChAdOx1-nCoV-19-vaccine-Barinthus Biotherapeutics/University-of-Oxford; chadox1-s; COVID-19 vaccine - AstraZeneca; COVID-19 vaccine - Barinthus Biotherapeutics/University of Oxford; Covishield; SII-ChAdOx1 nCoV-19; Vaxzevria; VTP-900

Latest Information Update: 28 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Oxford; Vaccitech
  • Developer AstraZeneca; Gamaleya Research Institute of Epidemiology and Microbiology; R-Pharm; University of Oxford
  • Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Marketed COVID 2019 infections

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(Combination therapy, Prevention) in Argentina (IM, Injection)
  • 28 Aug 2024 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(Combination therapy, In the elderly, Prevention, In adults) in United Arab Emirates (IM, Injection)
  • 27 Mar 2024 Astrazeneca withdraws marketing authorization application from EMA for AZD 1222 in COVID-2019 infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top